Alzheimer’s disease blood testing is approaching a decisive clinical transition after a large real-world study found that biomarker results allowed primary care physicians to diagnose the disease with accuracy approaching that of dementia specialists.
Interim results involving 1,310 patients showed that primary care diagnostic accuracy increased from 65% to 93% after physicians received results from C2N Diagnostics’ PrecivityAD2 blood test. Accuracy among specialists rose from 74% to 89%, while primary care physicians changed their working diagnosis in approximately 30% of cases and revised clinical-management plans for more than half of the patients.
The findings, presented at the Alzheimer’s Association International Conference in July 2026, arrive as blood-based biomarkers begin entering routine laboratory infrastructure. Neuroscience Research Australia and Roche Diagnostics Australia have launched an Asia-Pacific Centre of Excellence for Alzheimer’s Disease Diagnosis using automated blood and cerebrospinal-fluid biomarker testing, while United States laboratories are beginning to deploy Food and Drug Administration-cleared assays from Fujirebio Diagnostics and Roche Diagnostics.
The expanding diagnostic market is being driven partly by the arrival of amyloid-targeting treatments that require confirmation of Alzheimer’s pathology before treatment. Blood tests could reduce reliance on costly positron emission tomography scans and invasive lumbar punctures, allowing more patients to be evaluated before significant cognitive deterioration has occurred.
However, the phrase “Alzheimer’s blood test” can create a misleading impression of simplicity. The available assays do not all measure the same biomarkers, carry the same regulatory status or perform the same clinical role. They are not general-population screening tests, and a positive result does not necessarily establish that Alzheimer’s disease is responsible for a patient’s symptoms.
Why could 2026 become the turning point for Alzheimer’s blood-test adoption?
For decades, physicians investigating cognitive decline have relied on clinical histories, cognitive assessments, neurological examinations and structural brain imaging. Confirmation of amyloid pathology has generally required an amyloid PET scan or analysis of cerebrospinal fluid collected through lumbar puncture.
Both methods have important strengths, but neither is ideal for large-scale use. PET scanners are expensive and unevenly distributed, while lumbar punctures require trained clinicians and can be unacceptable to patients who are concerned about discomfort or complications.
Blood sampling is already available throughout healthcare systems. A validated assay that can be performed through established laboratory networks could move Alzheimer’s evaluation closer to primary care and reduce the number of patients referred immediately for specialised procedures.
The 2026 real-world results are important because they examined how physicians actually changed their diagnoses and management plans after seeing biomarker information. The study included 927 patients assessed by specialists and 383 evaluated in primary care, with cerebrospinal-fluid analysis, amyloid PET and expert consensus used to determine diagnostic accuracy.
Primary care physicians appeared particularly comfortable using a negative result to rule out Alzheimer’s pathology and investigate alternative explanations for cognitive problems. Specialists were more likely to use a positive result to make an immediate Alzheimer’s diagnosis without ordering another confirmatory test.
This distinction may influence how blood testing is introduced. Primary care adoption could initially focus on triage, while specialist centres use higher-performing tests more directly within treatment-selection pathways.
How do p-tau blood tests detect biological signs associated with Alzheimer’s disease?
Alzheimer’s pathology is associated with the accumulation of amyloid-beta plaques outside brain cells and abnormal forms of tau protein within the brain. Changes involving these proteins can be reflected in the bloodstream, although they are present at much lower concentrations than in cerebrospinal fluid.
Phosphorylated tau, commonly shortened to p-tau, has emerged as one of the most informative blood-based biomarker groups. Different assays measure phosphorylation at different positions on the tau protein, including p-tau181, p-tau217 and p-tau231.
P-tau217 has produced particularly strong results in studies examining the presence of brain amyloid pathology. Fujirebio Diagnostics’ Lumipulse test combines plasma p-tau217 and beta-amyloid 1-42 measurements into a ratio intended to identify whether a symptomatic patient is likely to have amyloid plaques associated with Alzheimer’s disease.
C2N Diagnostics’ PrecivityAD2 test uses high-resolution mass spectrometry to measure the beta-amyloid 42-to-40 ratio and the ratio between phosphorylated and non-phosphorylated tau at position 217. The results are combined through a proprietary algorithm to generate an Amyloid Probability Score.
Roche Diagnostics’ Elecsys Phospho-Tau 181P Plasma assay has a different purpose. It measures p-tau181 on Roche’s automated cobas laboratory platform and is primarily intended to help rule out amyloid pathology during the initial assessment of symptomatic adults.
The biomarkers are related, but the resulting tests should not be treated as interchangeable. Performance depends on the analyte, measurement technology, cutoff, patient population, disease prevalence and clinical setting.
What can the FDA-cleared Lumipulse Alzheimer’s blood test actually determine?
The FDA cleared Fujirebio Diagnostics’ Lumipulse G pTau217/beta-Amyloid 1-42 Plasma Ratio in May 2025, making it the first blood-based in vitro diagnostic authorised in the United States to aid in evaluating amyloid pathology associated with Alzheimer’s disease.
The agency reviewed data from 499 plasma samples obtained from cognitively impaired adults. Among patients receiving a positive result, 91.7% had amyloid plaques confirmed through PET imaging or cerebrospinal-fluid testing. Among those with a negative result, 97.3% also had a negative PET or cerebrospinal-fluid result. Fewer than 20% received an indeterminate classification.
These figures support clinically useful performance, but they do not mean that the test is 97% accurate in every population. Predictive values change when a test is used in groups with different underlying disease prevalence.
The Lumipulse assay is intended for people with signs and symptoms of cognitive decline who are being evaluated in specialist care. It is not authorised as a general screening test for healthy individuals and should not be interpreted without other clinical information.
A positive result indicates that amyloid pathology is likely to be present. It does not prove that amyloid is the sole cause of a patient’s symptoms, exclude the presence of another neurodegenerative disorder or determine whether the patient should receive a particular treatment.
How is Roche’s Elecsys pTau181 test different from Fujirebio’s Lumipulse assay?
The FDA cleared Roche Diagnostics’ Elecsys Phospho-Tau 181P Plasma assay in October 2025 for use in the initial evaluation of adults with cognitive complaints. The laboratory test operates on Roche’s cobas e immunoassay systems and has a reported analytical processing time of approximately 18 minutes.
Its principal regulatory role is exclusion rather than confirmation. A negative result is consistent with a negative amyloid PET scan and reduces the likelihood that the patient’s cognitive impairment is caused by amyloid pathology.
A positive result carries less certainty and should prompt further investigation. FDA documentation explicitly states that a positive Elecsys pTau181 result may not correspond with a positive amyloid PET scan.
The assay is not recommended for patients who have already been referred to specialist care, and its performance has not been established for predicting future dementia or monitoring treatment response.
This positioning could give Roche Diagnostics a large primary-care opportunity. A widely installed automated platform could allow physicians to rule out Alzheimer’s pathology earlier and direct patients toward evaluation for vascular, medication-related, psychiatric or other neurological causes of cognitive decline.
The commercial advantage of automation will still depend on reimbursement, laboratory availability, physician education and confidence in the result. A rapid laboratory test has limited value when clinicians do not understand whether it should rule out disease, confirm disease or trigger another investigation.
What does the PrecivityAD2 real-world study show about primary care diagnosis?
PrecivityAD2 is already offered through C2N Diagnostics’ accredited clinical laboratory, although the company’s FDA filing remained under regulatory review in the latest publicly available information. C2N Diagnostics submitted the mass-spectrometry-based test through the 510(k) pathway in October 2025.
The distinction between a laboratory-developed service and an FDA-cleared in vitro diagnostic is important. Clinical laboratories can offer certain tests under established laboratory regulations, but FDA review provides an additional assessment of analytical and clinical evidence for the authorised intended use.
The 2026 study nevertheless provides meaningful implementation evidence. Primary care physicians’ accuracy increased to 93%, closely approaching the 94% achieved by specialists evaluating the same patients after blood-test results became available.
Clinicians changed diagnoses in approximately one-third of primary care cases. Management plans, including referrals, additional tests and treatment decisions, changed in about half of the patients across primary and specialist settings.
These findings suggest that the value of a blood test is not limited to replacing PET or cerebrospinal-fluid testing. It may also shorten diagnostic pathways, prevent inappropriate treatment and help physicians decide which patients require specialist assessment.
The test does not remove the need for clinical judgement. A negative Alzheimer’s biomarker result does not mean that the patient has no neurological disease, while a positive result should be considered alongside symptoms, cognitive testing, imaging and potential coexisting conditions.
Could Alzheimer’s blood tests replace PET scans and lumbar punctures?
The Alzheimer’s Association has developed performance thresholds explaining when a blood biomarker can be used for triage and when it may substitute for PET imaging or cerebrospinal-fluid testing in specialist care.
Under the guideline, tests achieving at least 90% sensitivity and 75% specificity may be used as triage tools. A negative result can rule out Alzheimer’s pathology with high probability, while a positive result should be confirmed through PET or cerebrospinal-fluid testing.
A blood test reaching at least 90% sensitivity and 90% specificity may be used as a confirmatory substitute for PET or cerebrospinal-fluid biomarkers within the defined specialist population. The guideline warns that many commercially available tests do not meet these thresholds.
The most likely clinical model will therefore be tiered rather than absolute. Some assays will remove the need for additional testing in patients with clearly negative results. High-performing tests may directly confirm pathology in selected patients, while indeterminate or discordant results continue to require PET imaging or lumbar puncture.
PET also provides spatial information about amyloid distribution that a blood test cannot. Cerebrospinal fluid can support broader evaluation involving tau and other neurological biomarkers. These established tools are unlikely to disappear, but their use may become more targeted.
Why are Leqembi and Kisunla increasing demand for Alzheimer’s biomarker testing?
Disease-modifying anti-amyloid therapies are intended for selected patients with early symptomatic Alzheimer’s disease and confirmed amyloid pathology. This requirement creates a diagnostic step before treatment can begin.
Historically, limited PET capacity and specialist waiting lists have restricted the number of patients who can complete that evaluation. Blood tests could allow clinicians to identify likely candidates earlier and reserve more intensive procedures for uncertain cases.
The treatment decision remains considerably more complex than receiving a positive blood result. Patients may require magnetic resonance imaging, genetic-risk discussion, review of anticoagulant use and ongoing monitoring for amyloid-related imaging abnormalities.
A biomarker-positive patient may also be unsuitable for treatment because the disease is too advanced, comorbidities create excessive risk or the expected benefit does not justify the treatment burden.
Blood testing could therefore enlarge the diagnostic funnel without guaranteeing that every positive patient receives an anti-amyloid medicine. The greatest benefit may be enabling more informed discussions at an earlier disease stage.
Why should Alzheimer’s blood tests not be used for population-wide screening?
The biological changes associated with Alzheimer’s disease may begin many years before noticeable symptoms. That has encouraged public interest in testing healthy adults who want to know their future risk.
Current cleared tests are not intended for that purpose. They were validated in people already experiencing cognitive symptoms, where physicians are trying to determine the cause.
Using a diagnostic assay in asymptomatic populations can produce a very different balance of true and false results. Amyloid pathology may be present years before dementia develops, and some people with positive biomarkers may never experience clinically significant impairment during their lifetime.
A positive result could create anxiety, affect family and financial decisions and expose an individual to additional testing without providing a clearly beneficial treatment pathway.
The tests also do not predict precisely when symptoms will begin or how rapidly a person will decline. Roche’s cleared p-tau181 assay specifically states that its performance has not been established for predicting future dementia.
Research settings may use blood biomarkers to identify people for prevention trials, but that is different from routine screening sold directly to healthy consumers.
What did the Lumipulse recall reveal about laboratory-quality risks?
The transition from research to mass clinical testing introduces manufacturing and quality-control risks that are less visible in academic accuracy studies.
Fujirebio Diagnostics initiated a correction involving specific Lumipulse pTau217 reagent lots in December 2025, and the FDA classified the action as a Class II recall in February 2026. The affected lots could produce falsely elevated positive or indeterminate ratios, potentially leading patients to be classified incorrectly as having amyloid pathology or requiring unnecessary follow-up testing.
The company instructed laboratories to stop using the identified lots and review previous results with medical directors to determine whether physicians or patients should be contacted. The action involved 1,569 units distributed across multiple United States states.
The recall does not invalidate the overall blood-biomarker field or the Lumipulse platform. It demonstrates why laboratory diagnostics require continuous lot monitoring, quality controls and post-market surveillance.
False-positive Alzheimer’s results carry consequences beyond an inaccurate laboratory value. They can lead to psychological distress, inappropriate treatment, additional imaging and delayed investigation of the true cause of cognitive symptoms. The FDA identified false-positive and false-negative classifications as the principal risks of the Lumipulse test at the time of clearance.
As testing expands, health systems will need procedures for managing recalls, repeating affected results and explaining uncertainty to patients who may already be emotionally vulnerable.
Which diagnostic companies could benefit from the Alzheimer’s blood-test market?
Fujirebio Diagnostics holds an early regulatory position through the first FDA-cleared plasma ratio test. Its advantage rests on validated p-tau217 performance and an established Lumipulse laboratory platform.
Roche Diagnostics offers scale through its large installed base of cobas immunoassay systems. Its p-tau181 test has a narrower rule-out claim, but the ability to integrate testing into automated high-throughput laboratories could support wider adoption.
The new Asia-Pacific Centre of Excellence launched by Neuroscience Research Australia and Roche Diagnostics illustrates how platform companies may build regional diagnostic networks rather than market isolated assays. The centre plans to combine blood and cerebrospinal-fluid biomarkers with streamlined diagnostic and treatment pathways involving Roche and Eli Lilly Australia.
C2N Diagnostics has differentiated itself through mass spectrometry and an algorithm combining amyloid and tau ratios. PrecivityAD2 has generated strong real-world evidence, entered international partnerships and secured insurance coverage from selected payers, but FDA clearance would represent an important additional commercial milestone.
Other diagnostics companies are also developing p-tau217, amyloid-ratio and multi-analyte tests. The market may ultimately support several technologies differentiated by price, turnaround time, laboratory platform, regulatory indication and suitability for primary or specialist care.
The likely winners will not necessarily be the companies reporting the highest accuracy in a single study. Adoption will depend on reproducibility, access, reimbursement, physician education, assay stability and evidence generated in diverse populations.
Alzheimer’s blood tests are ready to transform triage, not replace the entire diagnostic process
The 2026 evidence strengthens the case that high-performing blood tests can improve Alzheimer’s diagnosis in ordinary clinical settings. Increasing primary care accuracy from 65% to more than 90% is not a marginal improvement. It could materially reduce diagnostic uncertainty and unnecessary referrals.
The greatest near-term value is likely to come from ruling out Alzheimer’s pathology. A reliable negative result can direct clinicians toward other neurological, psychiatric, vascular or medication-related explanations while reducing demand for PET imaging and lumbar punctures.
Positive results require more caution. The significance of a positive test depends on the assay, patient population and intended use. Some results can support confirmation in specialist care, while others should lead to additional investigation.
The market also needs stronger boundaries around screening. Commercial excitement should not encourage testing healthy people when the results cannot reliably predict whether or when dementia will develop.
The Lumipulse recall provides a timely reminder that the clinical value of a biomarker depends on the complete diagnostic system. Scientific validity, manufacturing consistency, laboratory operations, software thresholds and physician interpretation must all function correctly.
Alzheimer’s blood testing has crossed an important threshold. The central question is no longer whether blood biomarkers can detect amyloid pathology. It is whether health systems can deploy the right test, for the right patient, at the right point in the diagnostic pathway.
Handled carefully, the technology could shorten years of uncertainty to a more manageable sequence of clinical decisions. Handled poorly, it could generate a new population of worried patients carrying laboratory results they do not understand.
